Literature DB >> 7297020

Beta-blocking effect of single oral doses of carteolol.

R W Stoll, J H Cavanaugh, C M MacLeod.   

Abstract

Carteolol is a nonselective beta-adrenergic blocking agent with intrinsic sympathomimetic activity. The duration of beta blockade after single oral doses of carteolol was studied in normal men for 72 hr by determining the heart rate response to an external stimulus, bolus intravenous isoproterenol, and an internal stimulus (graded treadmill exercise designed to achieve 85% of the subjects' maximal heart rate in 12 min). Each subject first received 5 mg of carteolol and then, at 3-wk intervals, 2.5, 15, and 60 mg carteolol and placebo in a randomized, double-blind fashion. Beta blockade was maximal 1 to 2 hr after dosing and the heart rate response to isoproterenol and exercise remained less (P less than 0.05) than placebo responses for the 72 hr after each dose of carteolol. The double product (maximal exercise heart rate x systolic blood pressure during the twelfth minute of exercise) was below (P less than 0.05) baseline values for 24 hr after all doses, for 48 hr after 15 mg, and for 72 hr after 60 mg of carteolol.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297020     DOI: 10.1038/clpt.1981.211

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma.

Authors:  A Wellstein; D Palm; G Wiemer; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Kushida; Y Horai; K Chiba; T Suganuma
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.